(Q39649773)

13 September 2017

title

Therapeutic potential of antisense oligodeoxynucleotides in downregulating p53 oncogenic mutations in cancers (English)

1 reference

13 September 2017

Zhigang Xie

1

1 reference

13 September 2017

Wee Joo Chng

2

1 reference

13 September 2017

Kian Ghee Tay

3

1 reference

13 September 2017

Shaw Cheng Liu

4

1 reference

13 September 2017

Jianbiao Zhou

5

1 reference

13 September 2017

Chien-Shing Chen

6

1 reference

13 September 2017

publication date

30 September 2010

1 reference

13 September 2017

published in

Biotechnology Letters

1 reference

13 September 2017

volume

33

1 reference

13 September 2017

issue

2

1 reference

13 September 2017

page(s)

221-228

1 reference

https://scigraph.springernature.com/pub.10.1007/s10529-010-0423-5

13 September 2017

exact match

0 references

cites work

Raf: a strategic target for therapeutic development against cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

Rescuing the function of mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

Structure-function-rescue: the diverse nature of common p53 cancer mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

Exploiting the p53 pathway for the diagnosis and therapy of human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

Nucleic-acid therapeutics: basic principles and recent applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

Antisense technology: a selective tool for gene expression regulation and gene targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

Tumor-derived p53 mutants induce NF-kappaB2 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

Reactivation of mutant p53: molecular mechanisms and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

Mutant p53: an oncogenic transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

Antisense therapy in oncology: new hope for an old idea?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

Live or let die: the cell's response to p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

Antisense molecules for targeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

Strategies for therapeutic targeting of the p53 pathway in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10529-010-0423-5

10.1007/S10529-010-0423-5

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference